Oncology · Small MoleculeTrial Updateclinicalmid-term

Hutchmed Initiates Study on Food and PPI Effects on HMPL-760 Pharmacokinetics

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/18/2026, 12:31:23 AM

Assessment confidence: 78% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This study is critical as it evaluates the pharmacokinetics of HMPL-760 under varying conditions, which could lead to optimized dosing recommendations. The insights gained may significantly influence Hutchmed's competitive positioning in the oncology market. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 21 ranked evidence items (16 high-relevance).

Strategic Assessment

Understanding the pharmacokinetics could enhance dosing recommendations and improve patient outcomes, impacting market strategy. The strongest clinical anchor is A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov), entity match (hutchmed). In Oncology · Small Molecule, 3 regulatory and 4 competitive items passed relevance filtering for Hutchmed.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. This study may provide insights into the optimal administration conditions for HMPL-760, potentially influencing its market positioning against competitors.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Moderate corpus alignment. The findings may inform future labeling and dosing guidelines, impacting regulatory submissions and compliance.

Key Risks

Elevated medium regulatory exposure for Hutchmed could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Improved dosing recommendations could enhance patient outcomes and market acceptance, potentially increasing market share for HMPL-760 against competitors.
Upside for Hutchmed may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Lead sponsor: Hoffmann-La Roche. The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.

What Would Change This Assessment

This becomes more urgent if Monitor enrollment progress and results from the pharmacokinetics analysis once available.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Frutas Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E.
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govhigh relevance
Entity match (hutchmed)
FDA document
View source
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Meta
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hutchmed
HMPL-760

Commercial impact

medium

Improved dosing recommendations could enhance patient outcomes and market acceptance, potentially increasing market share for HMPL-760 against competitors.

Regulatory impact

medium

The findings may inform future labeling and dosing guidelines, impacting regulatory submissions and compliance.

What to watch

Monitor enrollment progress and results from the pharmacokinetics analysis once available.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.